Galectin-1, Cancer Cell Migration, Angiogenesis, and Chemoresistance

Galectins

Volumn , Issue , 2008, Pages 157-191

  Lefranc, Florence ^a,b   Le Mercier, Marie ^a   Mathieu, Véronique ^a   Kiss, Robert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Angiogenesis and vasculogenic mimicry; Cancer biology galectin 3; Galectin 1 cancer cell migration, angiogenesis, and chemoresistance

Indexed keywords

EID: 84889786537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470378076.ch9     Document Type: Chapter

References (176)

1. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006;16:137R-157R.
2. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29-41.
3. Califice S, Castronovo V, Van Den Brule F. Galectin-3 and cancer (Review). Int J Oncol 2004;25:983-992.
4. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005;10:267-275.
5. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004; 19:543-549.
6. Huflejt ME, Leffler H. Galectin-4 in normal tissues and cancer. Glycoconj J 2004; 20:247-255.
7. Saussez S, Cucu DR, Decaestecker C, Chevalier D, Kaltner H, Andre S, Wacreniez A, Toubeau G, Camby I, Gabius HJ, Kiss R. Galectin-7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 2006;13:999-1009.
8. Saussez S, Kiss R. Galectin-7. Cell Mol Life Sci 2006;63:686-697.
9. Bidon-Wagner N, Le Pennec JP. Human galectin-8 isoforms and cancer. Glycoconj J 2004;19:557-563.
10. Zick Y, Eisenstein M, Goren RA, Hadari YR, Levy Y, Ronen D. Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconj J 2004;19:517-526.
11. Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi TA, Kageshita T, Saita N, Nakamura T. Galectin-9 in physiological and pathological conditions. Glycoconj J 2004;19:593-600.
12. Yang RY, Hsu DK, Yu L, Ni J, Liu FT. Cell cycle regulation by galectin-12, a new member of the galectin superfamily. J Biol Chem 2001;276:20252-20260.
13. Lahm H, Andre S, Hoeflich A, Kaltner H, Siebert HC, Sordat B, von der Lieth CW,Wolf E, Gabius HJ. Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 2004;20:227-238.
14. van den Brule F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj J 2004;19:537-542.
15. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997;9:701-706.
16. Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, Shono M, Kanayama HO, Ellerhorst J, Lotan R, Raz A. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 2006;66:3114-3119.
17. Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T, Raz A. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 2005;65:7546-7553.
18. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, Bresalier RS, Raz A. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004;24:4395-4406.
19. Watt DJ, Jones GE, Goldring K. The involvement of galectin-1 in skeletal muscle determination, differentiation, and regeneration. Glycoconj J 2004;19:615-619.
20. Kami K, Senba E. Galectin-1 is a novel factor that regulates myotube growth in regenerating skeletal muscles. Curr Drug Targets 2005;6:395-405.
21. Gaudet AD, Steeves JD, TetzlaffW, Ramer MS. Expression and functions of galectin-1 in sensory and motoneurons. Curr Drug Targets 2005;6:419-425.
22. Horie H, Kadoya T, Sango K, Hasegawa M. Oxidized galectin-1 is an essential factor for peripheral nerve regeneration. Curr Drug Targets 2005;6:385-394.
23. Kato T, Ren CH, Wada M, Kawanami T. Galectin-1 as a potential therapeutic agent for amyotrophic lateral sclerosis. Curr Drug Targets 2005;6:407-418.
24. Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, Andre S, Gabius HJ, Khachigian L, Detjen KM, Rosewicz S. Galectin-1 interacts with the a5b1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem 2005;280:37266-37277.
25. Andre S, Kaltner H, Lensch M, Russwurm R, Siebert HC, Fallsehr C, Tajkhorshid E, Heck AJ, von Knebel Doeberitz M, Gabius HJ, Kopitz J. Determination of structural and functional overlap/divergence of five prototype galectins by analysis of the growthregulatory interaction with ganglioside GM1 in silico and in vitro on human neuroblastoma cells. Int J Cancer 2005;114:46-57.
26. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002;277:37169-37175.
27. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411-2422.
28. Decaestecker C, Debeir O, Van Ham P, Kiss R. Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 2007;27:149-176.
29. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004;36:1046-1069.
30. Belot N, Rorive S, Doyen I, Lefranc F, Bruyneel E, Dedecker R, Micik S, Brotchi J, Decaestecker C, Salmon I, Kiss R, Camby I. Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features. Glia 2001;36:375-390.
31. Bolteus AJ, Berens ME, Pilkington GJ. Migration and invasion in brain neoplasms. Curr Neurol Neurosci Rep 2001;1:225-232.
32. Giese A, Rief MD, Loo MA, Berens ME. Determinants of human astrocytoma migration. Cancer Res 1994;54:3897-3904.
33. Gladson CL. The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 1999;58:1029-1040.
34. Tonn JC, Goldbrunner R. Mechanisms of glioma cell invasion. Acta Neurochir Suppl 2003;88:163-167.
35. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996;84:359-369.
36. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001;114:2713-2722.
37. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1997;385:537-540.
38. Wehrle-Haller B, Imhof BA. Actin, microtubules and focal adhesion dynamics during cell migration. Int J Biochem Cell Biol 2003;35:39-50.
39. Belien AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999;144:373-384.
40. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
41. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001;61:6885-6891.
42. Andre S, Kojima S, Yamazaki N, Fink C, Kaltner H, Kayser K, Gabius HJ. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J Cancer Res Clin Oncol 1999;125:461-474.
43. Ellerhorst J, Nguyen T, Cooper DN, Lotan D, Lotan R. Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int J Oncol 1999;14: 217-224.
44. Moiseeva EP, Spring EL, Baron JH, de Bono DP. Galectin 1 modulates attachment, spreading and migration of cultured vascular smooth muscle cells via interactions with cellular receptors and components of extracellular matrix. J Vasc Res 1999;36:47-58.
45. Moiseeva EP, Williams B, Goodall AH, Samani NJ. Galectin-1 interacts with beta-1 subunit of integrin. Biochem Biophys Res Commun 2003;310:1010-1016.
46. van den Brule F, Califice S, Garnier F, Fernandez PL, Berchuck A, Castronovo V. Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab Invest 2003;83:377-386.
47. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 2001;91:167-172.
48. Clausse N, van den Brule F,Waltregny D, Garnier F, CastronovoV. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 1999; 3:317-325.
49. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 2005;7:522-527.
50. Lotan R, Belloni PN, Tressler RJ, Lotan D, Xu XC, Nicolson GL. Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. Glycoconj J 1994;11:462-468.
51. Moiseeva EP, Williams B, Samani NJ. Galectin 1 inhibits incorporation of vitronectin and chondroitin sulfate B into the extracellular matrix of human vascular smooth muscle cells. Biochim Biophys Acta 2003;1619:125-132.
52. Carsons S, Lavietes BB, Slomiany A, Diamond HS, Berkowitz E. Carbohydrate heterogeneity of fibronectins. Synovial fluid fibronectin resembles the form secreted by cultured synoviocytes but differs from the plasma form. J Clin Invest 1987; 80:1342-1349.
53. Fujiwara S, Shinkai H, Deutzmann R, Paulsson M, Timpl R. Structure and distribution of N-linked oligosaccharide chains on various domains of mouse tumour laminin. Biochem J 1988;252:453-461.
54. Allen HJ, Sucato D, Woynarowska B, Gottstine S, Sharma A, Bernacki RJ. Role of galaptin in ovarian carcinoma adhesion to extracellular matrix in vitro. J Cell Biochem 1990;43:43-57.
55. Skrincosky DM, Allen HJ, Bernacki RJ. Galaptin-mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptin-binding glycoproteins. Cancer Res 1993;53:2667-2675.
56. van den Brule FA, Buicu C, Baldet M, Sobel ME, Cooper DN, Marschal P, Castronovo V. Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 1995;209:760-767.
57. Elola MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE. Galectin-1 receptors in different cell types. J Biomed Sci 2005;12:13-29.
58. Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007;64:1679-1700.
59. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002;115:3729-3738.
60. Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj J 2004;21:9-15.
61. Ohannesian DW, Lotan D, Lotan R. Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1, and lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res 1994;54:5992-6000.
62. Seelenmeyer C, Wegehingel S, Lechner J, Nickel W. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci 2003;116:1305-1318.
63. Symons A, Cooper DN, Barclay AN. Characterization of the interaction between galectin-1 and lymphocyte glycoproteins CD45 and Thy-1. Glycobiology 2000; 10:559-563.
64. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 2001;11:12-26.
65. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius HJ, Kiss R. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 2002;61:585-596.
66. Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ, Kiss R. Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 2005;335:27-35.
67. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet 2000;16:83-87.
68. Eto K, Puzon-McLaughlin W, Sheppard D, Sehara-Fujisawa A, Zhang XP, Takada Y. RGD-independent binding of integrin a9b1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. J Biol Chem 2000;275:34922-34930.
69. Harvey S, Zhang Y, Landry F, Miller C, Smith JW. Insights into a plasma membrane signature. Physiol Genomics 2001;5:129-136.
70. Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I, Lefranc F, Kiss R. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 2007;127:2399-2410.
71. Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector JC, Salmon I, Yeaton P, Gabius HJ, Kiss R, Camby I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 2003;103:370-379.
72. Dudas SP, Yunker CK, Sternberg LR, Byrd JC, Bresalier RS. Expression of human intestinal mucin is modulated by the beta-galactoside binding protein galectin-3 in colon cancer. Gastroenterology 2002;123:817-826.
73. Ideo H, Seko A, Yamashita K. Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on the cell surface of human colon adenocarcinoma cells. J Biol Chem 2005;280:4730-4737.
74. Song S, Byrd JC, Mazurek N, Liu K, Koo JS, Bresalier RS. Galectin-3 modulates MUC2 mucin expression in human colon cancer cells at the level of transcription via AP-1 activation. Gastroenterology 2005;129:1581-1591.
75. Ueda S, Kuwabara I, Liu FT. Suppression of tumor growth by galectin-7 gene transfer. Cancer Res 2004;64:5672-5676.
76. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector JC, Zick Y, Salmon I, Danguy A, Kiss R, Gabius HJ. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 2002;50:392-401.
77. Nangia-Makker P, Conklin J, Hogan V, Raz A. Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents. Trends Mol Med 2002;8:187-192.
78. Fulcher JA, Hashimi ST, Levroney EL, Pang M, Gurney KB, Baum LG, Lee B. Galectin-1-matured human monocyte-derived dendritic cells have enhanced migration through extracellular matrix. J Immunol 2006;177:216-226.
79. Maeda N, Kawada N, Seki S, Arakawa T, Ikeda K, Iwao H, Okuyama H, Hirabayashi J, Kasai K,Yoshizato K. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem 2003;278:18938-18944.
80. Fukaya K, Hasegawa M, Mashitani T, Kadoya T, Horie H, Hayashi Y, Fujisawa H, Tachibana O, Kida S, Yamashita J. Oxidized galectin-1 stimulates the migration of Schwann cells from both proximal and distal stumps of transected nerves and promotes axonal regeneration after peripheral nerve injury. J Neuropathol Exp Neurol 2003;62:162-172.
81. Rabinovich GA, Sotomayor CE, Riera CM, Bianco I, Correa SG. Evidence of a role for galectin-1 in acute inflammation. Eur J Immunol 2000;30:1331-1339.
82. He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004;279:4705-4712.
83. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 2004;16:14-23.
84. Rorive S, Belot N, Decaestecker C, Lefranc F, Gordower L, Micik S, Maurage CA, Kaltner H, Ruchoux MM, Danguy A, Gabius HJ, Salmon I, Kiss R, Camby I. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 2001;33:241-255.
85. Le Mercier M, Kondo Y, Mathieu V, Camby I, Decaestecker C, Kiss R, Lefranc F. Decreasing galectin-1 expression in human experimental glioblastomas impairs the endoplasmic reticulum stress (ERS) response and increases temozolomide antitumor effects. In: 98th Annual Meeting of the American Association for Cancer Research (AACR). Los Angeles;2007.
86. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001; 20: 7486-7493.
87. Prior IA, Muncke C, Parton RG, Hancock JF. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol 2003;160:165-170.
88. Ashery U, Yizhar O, Rotblat B, Elad-Sfadia G, Barkan B, Haklai R, Kloog Y. Spatiotemporal organization of Ras signaling: rasosomes and the galectin switch. Cell Mol Neurobiol 2006;26:471-495.
89. Rotblat B, Niv H, Andre S, Kaltner H, Gabius HJ, Kloog Y. Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res 2004;64:3112-3118.
90. Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumukiza P, Darro F, Kiss R. Antigalectin compounds as potential anticancer drugs. Curr Med Chem 2006; 13:3513-3527.
91. Camby I, Lefranc F, Kiss R. In vivo siRNA-induced decreases of galectin-1 expression in experimental models of human orthotopic glioblastoma xenografts contributes therapeutic benefits. In: 97th Annual Meeting of the American Association for Cancer Research (AACR). Washington, DC;2006.
92. Saussez S, Decaestecker C, Lorfevre F, Cucu DR, Mortuaire G, Chevalier D,Wacreniez A, Kaltner H, Andre S, Toubeau G, Camby I, Gabius HJ, Kiss R. High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas. Int J Oncol 2007;30:1109-1117.
93. van den Brule FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 2001;193:80-87.
94. Chiariotti L, Berlingieri MT, Battaglia C, Benvenuto G, Martelli ML, Salvatore P, Chiappetta G, Bruni CB, Fusco A. Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 1995;64:171-175.
95. Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815-822.
96. Endharti AT, Zhou YW, Nakashima I, Suzuki H. Galectin-1 supports survival of naive T cells without promoting cell proliferation. Eur J Immunol 2005;35:86-97.
97. Moiseeva EP, Javed Q, Spring EL, de Bono DP. Galectin 1 is involved in vascular smooth muscle cell proliferation. Cardiovasc Res 2000;45:493-502.
98. Sanford GL, Harris-Hooker S. Stimulation of vascular cell proliferation by betagalactoside specific lectins. FASEB J 1990;4:2912-2918.
99. Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, Cantz M, Gabius HJ. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 2001;276:35917-35923.
100. Andersen H, Jensen ON, Moiseeva EP, Eriksen EF. A proteome study of secreted prostatic factors affecting osteoblastic activity: galectin-1 is involved in differentiation of human bone marrow stromal cells. J Bone Miner Res 2003;18:195-203.
101. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 2004;5:241-251.
102. YamaokaK,Mishima K, NagashimaY, AsaiA, SanaiY, Kirino T. Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res 2000;59:722-730.
103. Adams L, Scott GK, Weinberg CS. Biphasic modulation of cell growth by recombinant human galectin-1. Biochim Biophys Acta 1996;1312:137-144.
104. Vas V, Fajka-Boja R, Ion G, Dudics V, Monostori E, Uher F. Biphasic effect of recombinant galectin-1 on the growth and death of early hematopoietic cells. Stem Cells 2005;23:279-287.
105. Wells V, Davies D, Mallucci L. Cell cycle arrest and induction of apoptosis by beta galactoside binding protein (beta GBP) in human mammary cancer cells. A potential new approach to cancer control. Eur J Cancer 1999;35:978-983.
106. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
107. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274.
108. Spiotto MT, Schreiber H. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun 2005;5:8.
109. Hirabayashi J, Ayaki H, Soma G, Kasai K. Cloning and nucleotide sequence of a fulllength cDNA for human 14 kDa beta-galactoside-binding lectin. Biochim Biophys Acta 1989;1008:85-91.
110. Joubert R, Kuchler S, Zanetta JP, Bladier D, Avellana-Adalid V, Caron M, Doinel C, Vincendon G. Immunohistochemical localization of a beta-galactoside-binding lectin in rat central nervous system. I. Light- and electron-microscopical studies on developing cerebral cortex and corpus callosum. Dev Neurosci 1989;11:397-413.
111. Wollina U, Schreiber G, Gornig M, Feldrappe S, Burchert M, Gabius HJ. Sertoli cell expression of galectin-1 and -3 and accessible binding sites in normal human testis and Sertoli cell only-syndrome. Histol Histopathol 1999;14:779-784.
112. Berberat PO, Friess H,Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A, BuchlerMW. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 2001;49:539-549.
113. Gillenwater A, Xu XC, el-Naggar AK, Clayman GL, Lotan R. Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996;18:422-432.
114. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, Liu FT, Cardesa A, Campo E. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 1997;113:1906-1915.
115. Shimonishi T, Miyazaki K, Kono N, Sabit H, Tuneyama K, Harada K, Hirabayashi J, Kasai K, Nakanuma Y. Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 2001;32:302-310.
116. Roberts AA, Amano M, Felten C, Galvan M, Sulur G, Pinter-Brown L, Dobbeling U, Burg G, Said J, Baum LG. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod Pathol 2003;16:543-551.
117. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ, Giaccia AJ, Koong AC. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005;23:8932-8941.
118. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925.
119. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-214.
120. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
121. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-651.
122. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
123. Onn A, Fidler IJ. Metastatic potential of human neoplasms. In Vivo 2002;16:423-429.
124. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2:83-90.
125. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-799.
126. Bockhorn M, Roberge S, Sousa C, Jain RK, Munn LL. Differential gene expression in metastasizing cells shed from kidney tumors. Cancer Res 2004;64:2469-2473.
127. Buttiglieri S, Deregibus MC, Bravo S, Cassoni P, Chiarle R, Bussolati B, Camussi G. Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J Biol Chem 2004;279:4136-4143.
128. Goswami S, Wang W, Wyckoff JB, Condeelis JS. Breast cancer cells isolated by chemotaxis from primary tumors show increased survival and resistance to chemotherapy. Cancer Res 2004;64:7664-7667.
129. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 2003;107:707-714.
130. Kinoshita K, Taupin DR, Itoh H, Podolsky DK. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 2000;20:4680-4690.
131. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Coppola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2003;63:7708-7716.
132. Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a ?molecular switch? for induction of cell migration. J Cell Biol 1998; 140:961-972.
133. Cho SY, Klemke RL. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol 2000;149:223-236.
134. Kain KH, Gooch S, Klemke RL. Cytoplasmic c-Abl provides a molecular ?Rheostat? controlling carcinoma cell survival and invasion. Oncogene 2003;22:6071-6080.
135. McCormick F. Cancer: survival pathways meet their end. Nature 2004;428:267-269.
136. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor Trk B. Nature 2004;430:1034-1039.
137. Lefranc F, James S, Camby I, Gaussin JF, Darro F, Brotchi J, Gabius J, Kiss R. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. J Neurosurg 2005;102:706-714.
138. Lefranc F,Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected antitumor agent, and its potential for the treatment of glioblastoma (review)Int J Oncol 2006;28:1021-1030.
139. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
140. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
141. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007;170:1-15.
142. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-752.
143. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003;3:411-421.
144. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-684.
145. Fukumori T, Kanayama HO, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat 2007;10:101-108.
146. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000; 156:899-909.
147. John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 2003;9:2374-2383.
148. Inufusa H, Nakamura M, Adachi T, Aga M, Kurimoto M, Nakatani Y,Wakano T, Miyake M, Okuno K, Shiozaki H, Yasutomi M. Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol 2001;19:913-919.
149. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002;94:1854-1862.
150. Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D'Egidio M, Piccolo E, Tinari N, Nifantiev N, Iacobelli S. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006;16:210-220.
151. D'Haene N, Maris C, Sandras F, Dehou MF, Remmelink M, Decaestecker C, Salmon I. The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkin's and Hodgkin's lymphomas. Int J Immunopathol Pharmacol 2005; 18:431-443.
152. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006;103:15975-15980.
153. Lefranc F, Sadeghi N, Metens T, Brotchi J, Salmon I, Kiss R. Characterization of gastrininduced cytostatic effect on cell proliferation in experimental malignant gliomas. Neurosurgery 2003;52:881-890; discussion 890-881.
154. Thakker DR, Natt F, Husken D, Maier R, Muller M, van der Putten H, Hoyer D, Cryan JF. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 2004;101:17270-17275.
155. Ozawa K, Tsukamoto Y, Hori O, Kitao Y, Yanagi H, Stern DM, Ogawa S. Regulation of tumor angiogenesis by oxygen-regulated protein 150, an inducible endoplasmic reticulum chaperone. Cancer Res 2001;61:4206-4213.
156. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis 2006;11:5-13.
157. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance, and hypoxia-related therapies. Cancer Treat Rev 2003;29:297-307.
158. Berger BJ, Muller TS, Buschmann IR, Peters K, Kirsch M, Christ B, Prols F. High levels of the molecular chaperone Mdg1/ERdj4 reflect the activation state of endothelial cells. Exp Cell Res 2003;290:82-92.
159. Prols F, Mayer MP, Renner O, Czarnecki PG, Ast M, Gassler C,Wilting J, Kurz H, Christ B. Upregulation of the cochaperone Mdg1 in endothelial cells is induced by stress and during in vitro angiogenesis. Exp Cell Res 2001;269:42-53.
160. Buttery R, Monaghan H, Salter DM, Sethi T. Galectin-3: differential expression between small-cell and non-small-cell lung cancer. Histopathology 2004;44:339-344.
161. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 2008; epub ahead of print.
162. Kroemer G, J€a€attel€a M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005;5:886-897.
163. Hori O, Ichinoda F, Yamaguchi A, Tamatani T, Taniguchi M, Koyama Y, Katayama T, Tohyama M, Stern DM, Ozawa K, Kitao Y, Ogawa S. Role of Herp in the endoplasmic reticulum stress response. Genes Cells 2004;9:457-469.
164. Kurisu J, Honma A, Miyajima H, Kondo S, Okumura M, Imaizumi K. MDG1/ERdj4, an ER-resident DnaJ family member, suppresses cell death induced by ER stress. Genes Cells 2003;8:189-202.
165. Andre S, Pieters RJ, Vrasidas I, Kaltner H, Kuwabara I, Liu FT, Liskamp RM, Gabius HJ. Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates. ChemBioChem 2001;2:822-830.
166. Sorme P, Kahl-Knutsson B, Wellmar U, Magnusson BG, Leffler H, Nilsson UJ. Design and synthesis of galectin inhibitors. Methods Enzymol 2003;363:157-169.
167. Ingrassia L, Nshimyumukiza P, Dewelle J, Lefranc F, Wlodarczak L, Thomas S, Dielie G, Chiron C, Zedde C, Tisnes P, van Soest R, Braekman JC, Darro F, Kiss R. A lactosylated steroid contributes in vivo therapeutic benefits in experimental models of mouse lymphoma and human glioblastoma. J Med Chem 2006;49:1800-1807.
168. Hamm CW. Antiintegrin therapy. Annu Rev Med 2003;54:425-435.
169. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004;64:9018-9026.
170. François C, vanVelthovan R, De Lathouwer O, Moreno C, Peltier A, Kaltner H, Salmon I, Gabius HJ, Danguy A, Decaestecker C, Kiss R. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 1999;112:194-203.
171. Saussez S, Nonclercq D, Laurent G, Wattiez R, André S, Kaltner H, Gabius HJ, Kiss R, Toubeau G. Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster. Histochem Cell Biol 2005;123:29-41.
172. Cindolo L, Benvenuto G, Salvatore P, Pero R, Salvatore G, Mirone V, Prezioso D, Altieri V, Bruni CB, Chiariotti L. Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 1999;84:39-43.
173. Bozić M, Petronijević M, Milenković S, Atanacković J, Lazić J, Vićovac Lj. Galectin-1 and galectin-3 in the trophoblast of the gestational trophoblastic desease. Placenta 2004;25:797-802.
174. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW, Lee CW, Lee JS, Park ST. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007;120:2331-2338.
175. Szoke T, Kayser K, Baumhakel JD, Trojan I, Furak J, Tiszlavicz L, Horvath A, Szluha K, Gabius HJ, Andre S. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 2005;69:167-174.
176. Fitzner B,Walzel H, Sparmann G, Emmrich J, Liebe S, Jaster R. Galectin-1 is an inductor of pancreatic stellate cell activation. Cell Signal 2005;17:1240-1247.